Loading…
Employees: 1,760
Size Fuji Pharma (4554.T) is a Japan Health Care company (Pharmaceuticals: Major) with a market value of $294M, the 1368th largest of 1,379 Japan companies the cockpit tracks. Shares closed at ¥1,778 on 6 Nov 2026.
Performance Over six months the shares fell 18.9%, against -25.9% for the median peer and +1.8% for the Japan market (cap-weighted) — 5th highest of 20 in its peer set.
Growth Revenue grew 20.4% over the last twelve months (peer median +1.7%); the operating margin is 11.7% (peer median 4.9%).
Valuation It trades at 18.6× forward earnings against a peer median of 18.2× (3rd cheapest of 5).
Price implies For today's price to make sense, revenue must grow about -7% a year for seven years (Req g). Recent delivered growth is +9%, so the hurdle is -16 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 1.8 points above its cost of capital (5.0% WACC).
Next results Next results expected around 10 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ¥60.1B | ¥51.7B | ¥46.1B | ¥40.9B | ¥35.4B |
| Revenue growth | — | +12% | +13% | +15% | — |
| Gross profit | ¥23.7B | ¥19.3B | ¥16.5B | ¥15.4B | ¥13.6B |
| EBITDA | ¥11.1B | ¥8.96B | ¥7.56B | ¥6.88B | ¥6.52B |
| Net income | ¥2.99B | ¥3.00B | ¥6.15B | ¥3.44B | ¥2.70B |
| Free cash flow | n/a | ¥3.82B | ¥1.37B | -¥1.41B | -¥5.75B |
| Capital expenditure | n/a | ¥4.33B | ¥7.08B | ¥5.14B | ¥12.7B |
| Total debt | ¥28.9B | ¥30.9B | ¥29.3B | ¥28.9B | ¥24.6B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 4554.T | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +1.0% | -11.0% | highest of 20 |
| 6-month return | -18.9% | -25.9% | 5th highest of 20 |
| Distance from 52-week high | -30.5% | -47.4% | 5th highest of 20 |
| Revenue growth (TTM) | +20.4% | +1.7% | 3rd highest of 19 |
| Operating margin | 11.7% | 4.9% | 2nd highest of 20 |
| Forward P/E | 18.6× | 18.2× | 3rd cheapest of 5 |
| Growth the price implies (Req g, 7 yrs) | -6.8% | 7.9% | 2nd least demanding of 13 |
| Growth delivered (Del g) | +8.9% | +1.4% | 2nd highest of 13 |
| Hurdle (Req g minus delivered) | -15.7 pp | +8.7 pp | 3rd least demanding of 13 |
| ROIC minus cost of capital | +1.8 pp | -5.7 pp | 3rd highest of 19 |
| EV / EBITDA | 5.9× | 17.7× | 3rd cheapest of 9 |
| Net debt / EBITDA | 1.7× | 0.4× | 5th least indebted of 9 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Fuji Pharma 4554.T | Japan | $294M | -19% | +20% | 12% | 18.6× | -6.8% | +8.9% |
| Shinpoong Pharmaceutical 019170.KS | South Korea | $300M | -32% | +6% | 1% | n/a | 39.9% | +3.5% |
| Shanxi C&Y Pharmaceutical 300254.SZ | China | $308M | -44% | -6% | 9% | n/a | 10.1% | +0.6% |
| Formycon FYB.DE | Germany | $280M | -26% | +18% | -26% | n/a | n/a | n/a |
| Emergent BioSolutions EBS | United States | $312M | -27% | -18% | 5% | 16.1× | -0.1% | -13.7% |
| Zhejiang Zhenyuan Share 000705.SZ | China | $312M | -25% | -33% | -5% | n/a | n/a | n/a |
| Ocugen OCGN | United States | $314M | -39% | -11% | -1,444% | n/a | n/a | n/a |
| Swedencare SECARE.ST | Sweden | $315M | -23% | +3% | 7% | 23.4× | 5.5% | +62.1% |
| Kitazato 368A.T | Japan | $317M | -9% | +9% | 52% | 12.0× | -16.7% | +5.4% |
| Zhejiang Shengda Bio-Pharm 603079.SS | China | $318M | -29% | -3% | 7% | n/a | 5.7% | -0.3% |
| Shandong Sito Bio-technology 300583.SZ | China | $318M | -26% | +19% | 6% | n/a | 2.7% | +2.3% |
| GC Corp. 005250.KS | South Korea | $319M | -32% | +10% | 1% | n/a | 31.5% | +7.4% |
| Eikon Therapeutics EIKN | United States | $320M | -41% | n/a | n/a | n/a | n/a | n/a |
| Enanta Pharmaceuticals ENTA | United States | $320M | -28% | +1% | -90% | n/a | n/a | n/a |
| Ind-Swift Laboratories INDSWFTLAB.NS | India | $321M | +149% | +66% | 9% | n/a | n/a | n/a |
| 6467 6467.TW | Taiwan | $322M | n/a | n/a | -2,618% | n/a | n/a | n/a |
| Hainan Huluwa Pharmaceutical 605199.SS | China | $322M | -21% | -32% | -58% | n/a | 2.5% | -4.9% |
| Solara Active Pharma Sciences SOLARA.NS | India | $323M | +23% | +27% | 8% | 20.2× | 37.7% | -3.2% |
| Enwei Pharmaceutical 301331.SZ | China | $326M | -20% | -7% | 5% | n/a | 15.1% | +7.3% |
| Hangzhou Tianmushan Pharmaceutical Enterprise 600671.SS | China | $327M | -10% | -19% | 5% | n/a | 22.5% | +0.5% |
| Beihai Gofar Chuanshan Biological 600538.SS | China | $328M | -38% | +10% | -8% | n/a | n/a | n/a |